Revolution Medicines (RVMD) Company Report

Revolution Medicines expects the RASolute 302 trial for daraxonrasib monotherapy in previously treated pancreatic cancer to read out in the first half of 2026, which is highlighted as the most significant event for the company.
The company anticipates providing initial durability data for daraxonrasib in first-line pancreatic cancer (monotherapy and combination with chemotherapy) in the first half of 2026, and initial colorectal cancer data later in 2026 to guide its registration strategy.
Revolution Medicines has initiated a total of five Phase 3 studies, with four in pancreatic cancer, including the RATIONALE 305 trial for zoldonrasib in combination with chemotherapy, and is preparing for a swift NDA submission for daraxonrasib, supported by a National Priority Voucher.

3 days ago

Transcript

Revolution Medicines Details Upcoming Clinical Trial Readouts and Regulatory Preparedness

RVMD

New Projects/Investments

Guidance Update

Revolution Medicines anticipates the readout of the pivotal RASolute 302 trial for daraxonrasib in previously treated pancreatic cancer in the first half of 2026, which is highlighted as the most significant event.
Initial durability data for daraxonrasib in first-line pancreatic cancer and initial data for colorectal cancer are also expected in the first half and later in 2026, respectively, to inform registration strategies.
The company is prepared for a swift NDA submission for daraxonrasib, leveraging a National Priority Voucher and a phased information submission process with the FDA.
Revolution Medicines has initiated five Phase 3 studies, including the RATIONALE 305 trial for zoldonrasib in first-line pancreatic cancer, and has fully enrolled a second-line plus cohort for zoldonrasib in lung cancer.

3 days ago

Transcript

Revolution Medicines Provides Updates on Clinical Trials and Commercialization Strategy

RVMD

New Projects/Investments

Guidance Update

Product Launch

Revolution Medicines anticipates the readout of the RASolute 302 trial in previously treated pancreatic cancer in the first half of 2026, which is highlighted as the most notable event of the year.
The company expects to provide initial durability data for daraxonrasib monotherapy and combination with chemotherapy in first-line pancreatic cancer in the first half of 2026, and initial data on colorectal cancer later in 2026.
Revolution Medicines is prepared for a swift NDA submission for daraxonrasib, supported by a National Priority Voucher and pre-market commercialization efforts, including a rolling submission process with the FDA.
The company has five Phase III studies underway, four in pancreatic cancer, and is advancing zoldonrasib, a G12D selective inhibitor, in first-line pancreatic cancer (RATIONALE 305 trial) and has fully enrolled a second-line plus cohort for zoldonrasib in lung cancer.

3 days ago

Transcript

Revolution Medicines Reports Q4 and Full Year 2025 Results and Provides 2026 Guidance

RVMD

Earnings

Guidance Update

New Projects/Investments

Revolution Medicines reported its Q4 and full year 2025 financial results, with key figures for the quarter including cash and investments, net loss, R&D expenses, and G&A expenses, as detailed in the table below.
For full year 2026, the company provided GAAP operating expense guidance, including estimated non-cash stock-based compensation, reflecting the progression and expansion of clinical development programs and increased commercial preparation activities.
The company announced significant pipeline advancements, with daraxonrasib and zoldonrasib both receiving FDA Breakthrough Therapy Designation. Daraxonrasib also received a Commissioner's National Priority Voucher for pancreatic cancer.
Revolution Medicines is actively building a global oncology enterprise and recruiting a field sales team in preparation for its first commercial launch, initially focused on the U.S. market.

Metric	Q4 2025	FY 2026 (Guidance)
Cash and Investments ($USD Billions)	$2.03	N/A
R&D Expenses ($USD Millions)	$294.9	N/A
G&A Expenses ($USD Millions)	$66.7	N/A
Net Loss ($USD Millions)	$364.9	N/A
GAAP Operating Expenses ($USD Billions)	N/A	$1.6 - $1.7
Estimated Non-Cash Stock-Based Compensation ($USD Millions)	N/A	$180 - $200

Feb 25, 2026, 9:30 PM

Transcript

Revolution Medicines Reports Q4 2025 Results and Provides 2026 Operating Expense Guidance

RVMD

Earnings

Guidance Update

New Projects/Investments

Revolution Medicines reported a net loss of $364.9 million for Q4 2025, compared to $194.6 million for Q4 2024, with R&D expenses increasing to $294.9 million and G&A expenses rising to $66.7 million for the quarter.
The company concluded Q4 2025 with $2.03 billion in cash and investments, partially due to a strategic partnership with Royalty Pharma, which provided $250 million in June 2025 and retains an additional $1.75 billion in committed capital.
For fiscal year 2026, Revolution Medicines projects GAAP operating expenses to range between $1.6 billion and $1.7 billion, including an estimated $180 million to $200 million in non-cash stock-based compensation.
Key pipeline advancements include the completion of global enrollment for the daraxonrasib RASolute 302 trial, with a readout anticipated in the first half of 2026, and zoldonrasib receiving Breakthrough Therapy Designation and initiating the RESOLUTE-305 trial.
Revolution Medicines is actively preparing for its first commercial launch, building a global oncology enterprise through strategic hires and the ongoing recruitment of its first field sales team.

Feb 25, 2026, 9:30 PM

Transcript

Revolution Medicines Reports Q4 2025 Results and Provides 2026 Guidance

RVMD

Earnings

Guidance Update

New Projects/Investments

Revolution Medicines reported a net loss of $364.9 million for the fourth quarter of 2025 and expects full year 2026 GAAP operating expenses to be between $1.6 billion and $1.7 billion.
The company ended Q4 2025 with $2.03 billion in cash and investments, with an additional $1.75 billion in committed capital available from its partnership with Royalty Pharma.
Global enrollment is complete for the RASolute 302 trial of daraxonrasib in second-line metastatic pancreatic cancer, with a readout expected in the first half of 2026.
Revolution Medicines initiated RASolute 305 for zoldonrasib in first-line pancreatic cancer and plans to initiate RASolute 309 (zoldonrasib plus daraxonrasib) in the second half of 2026.
The company dosed the first patient for its fourth RAS(ON) inhibitor, RMC-5127, and plans to begin clinical development of a new class of RAS(ON) inhibitors later in 2026, designed to overcome drug resistance.

Feb 25, 2026, 9:30 PM

Transcript

Revolution Medicines Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance

RVMD

Earnings

Guidance Update

New Projects/Investments

Revolution Medicines, Inc. reported a net loss of $1.1 billion for the full year ended December 31, 2025, with research and development expenses totaling $987.3 million.
As of December 31, 2025, the company held $2.0 billion in cash, cash equivalents, and marketable securities.
For the full year 2026, the company anticipates GAAP operating expenses to be between $1.6 and $1.7 billion.
Key clinical updates include an expected readout for the Phase 3 RASolute 302 trial in the first half of 2026, the initiation of the RASolute 305 Phase 3 trial for zoldonrasib, and FDA Breakthrough Therapy designation for zoldonrasib in previously treated NSCLC.
The company plans to initiate three additional Phase 3 trials in 2026 and a Phase 1 trial for a new class of RAS(ON) inhibitors in the fourth quarter of 2026.

Feb 25, 2026, 9:05 PM

8-K

Revolution Medicines Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance

RVMD

Earnings

Guidance Update

New Projects/Investments

Revolution Medicines reported a net loss of $364.9 million for the fourth quarter ended December 31, 2025, and a net loss of $1.1 billion for the full year ended December 31, 2025.
As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $2.0 billion.
The company expects full year 2026 GAAP operating expenses to be between $1.6 and $1.7 billion.
Revolution Medicines anticipates a readout for the RASolute 302 Phase 3 trial (daraxonrasib in PDAC) in the first half of 2026, initiated RASolute 305 (zoldonrasib in PDAC), and plans to initiate RASolve 308 (zoldonrasib in NSCLC) in the first half of 2026.
The company also advanced its fourth RAS(ON) inhibitor, RMC-5127, into the clinic and plans to initiate a Phase 1 trial for a new class of RAS(ON) inhibitors in the fourth quarter of 2026.

Feb 25, 2026, 9:02 PM

Press Release

Revolution Medicines Provides Updates on Daraxonrasib and Zoldonrasib Clinical Trials, New RAS Inhibitor, and Global Strategy

RVMD

New Projects/Investments

Guidance Update

Revolution Medicines expects top-line data in the first half of 2026 for daraxonrasib from the RASolute 302 Phase III study in second-line pancreatic ductal adenocarcinoma (PDAC), with overall survival (OS) as the main endpoint.
The company has initiated the RASolute 303 study for daraxonrasib in first-line metastatic PDAC, which is now open for enrollment and anticipated to enroll swiftly.
Two new Phase III studies for zoldonrasib in first-line PDAC have been announced, one combining it with chemotherapy and another with daraxonrasib, aiming to provide multiple treatment options.
Revolution Medicines is developing RM-055, a new class of RAS inhibitors, with an expected initiation of a clinical trial for the first compound by the end of 2026.
The company is committed to a global alone approach for commercialization, supported by a $2 billion funding agreement with Royalty Pharma, and does not plan to pursue ex-U.S. partnerships.

Feb 11, 2026, 2:30 PM

Transcript

Revolution Medicines Provides Updates on RASolute Studies, Pipeline, and Global Strategy

RVMD

New Projects/Investments

Product Launch

Guidance Update

Top-line data for the RASolute 302 study in second-line pancreatic ductal adenocarcinoma (PDAC) is anticipated in the first half of 2026, with Overall Survival (OS) as the main endpoint.
The RASolute 303 study for darovasib in first-line metastatic PDAC has opened for enrollment, with the company expecting swift participation due to high patient and investigator interest.
Revolution Medicines plans to initiate a clinical trial for RM055, a novel class of RAS inhibitors, by the end of 2026, and expects to provide updates on its colorectal cancer strategy and data in 2026.
The company is committed to a global, go-it-alone approach, opting against ex-US partnerships.

Feb 11, 2026, 2:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Revolution Medicines.

Q4 2025

Feb 25, 2026

→

Q3 2025

Nov 5, 2025

→

Q2 2025

Aug 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Mark Goldsmith say about margins?What are Revolution Medicines's strategic priorities?How is Revolution Medicines positioned vs competitors?How did Revolution Medicines do last quarter?

Revolution Medicines (RVMD)

Analyst Earnings Quarterly Reports

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Executives

Mark Goldsmith

Alan Sandler

Jack Anders

Jeff Cislini

Margaret Horn

Steve Kelsey

Wei Lin

Xiaolin Wang

Board Members

Alexis Borisy

Elizabeth McKee Anderson

Flavia Borellini

Frank Clyburn

Lorence Kim

Sandra Horning

Sushil Patel

Thilo Schroeder

Analyst Coverage

Michael Schmidt

Marc Frahm

Alec Stranahan

Laura Prendergast

Jonathan Chang

Asthika Goonewardene

Charles Zhu

Jay Olson

Leonid Timashev

Poorna Kannan

Eric Joseph

Joseph Catanzaro

Albert Agustinus

Ami Fadia

Brian Chang

Brian Cheng

Ellie Merle

Faisal Khurshid

Jenna Li

Kalpit Patel

Kelly Shi

Long Yang

Mia Morgan

Peter Lawson

Sean Callaghan

Yuxi Dong

Alex Ramsey

Andrea Newkirk

Benjamin Burnett

Eliana Merle

Jay Olsen

Kevin DeGeeter

Marc Fromm

Matthew Harrison

Samantha Meadows-Ortiz

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent